
X
Astellas to work with Adaptimmune to develop ‘off the shelf’ T-cell therapies
https://pharmaphorum.com/news/astellas-to-work-with-adaptimmune-to-develop-off-the-shelf-t-cell-therapies/
Adaptimmune has more good news from its SPEAR T-cell therapy, yesterday unveiling encouraging early results in four patients with myxoid/round cell liposarcoma (MRCLS).
T-cell trial will include controversial chemo agent fludarabine.
Biotech says “robust” clinical response in early stage trial.
Regulator asks for information on trial design.